Skip to content
AnalystLens

Corteva, Inc. 8-K Report, Financial Results (Feb 3, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 3, 2026
Period End
February 3, 2026
Security
CTVA
In the record · 2019–202610-K710-Q238-K85

CTVA filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 85 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’21Feb ’21
  2. Restructuring8-K · Aug ’22Aug ’22
  3. Impairment8-K · Nov ’23Nov ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 3, 2026. Cited figures are marked; the original filing is the authoritative source.

Corteva reported a mixed but improving fourth quarter and full year 2025.

Fourth-quarter net sales fell 2% to $3.91 billiona (organic sales down 4%), with volume down 5% due largely to seasonal shifts of North American seed and crop protection deliveries into the first quarter of 2026. GAAP results were weak: a loss from continuing operations of $537 million (EPS of $(0.80)), driven by a $610 million pre-tax charge for the Bayer litigation resolution and a $132 million tax valuation allowance on a Brazilian entity. Non-GAAP operating EBITDA fell 15% to $446 million and operating EPS fell 31% to $0.22.

Crop Protection was the main drag, with segment EBITDA down 22% on price pressure in Latin America and higher compensation and R&D costs. For the full year, results were stronger. Net sales rose 3% to $17.40 billionb (organic sales up 4%), GAAP EPS from continuing operations was $1.75 (up 43%), and operating EPS was $3.34 (up 30%).

Seed was the standout, with segment EBITDA up 19% to $2.64 billionc and margins up about 340 basis points. Free cash flow reached $2.9 billion, up 69%, and the company returned over $1.5 billion to shareholders. The company guided 2026 operating EBITDA to $4.0-$4.2 billion (about 7% growth at the midpoint) and operating EPS to $3.45-$3.70.

The most significant strategic development is the comprehensive resolution of all litigation with Bayer. Management says the agreement accelerates the path to royalty neutrality to 2026, two years early, and expands freedom to operate and out-licensing opportunities in corn, canola, and cotton.

Management estimates roughly $1 billiond of aggregate earnings upside over the next decade, though the settlement carries a $610 million cash outflow, largely in the first quarter of 2026. The company also reiterated that the planned separation remains on track for the second half of 2026, with several milestones (new CEO, SpinCo branding, Form 10 amendments) expected in the first half.

02—Key points

Key Highlights

  1. Q4 2025 GAAP loss from continuing operations of $537M (EPS $(0.80)) was driven largely by a $610M pre-tax Bayer litigation resolution charge and a $132M Brazil tax valuation allowance.
  2. Q4 operating EBITDA fell 15% to $446M and operating EPS fell 31% to $0.22, with Crop Protection EBITDA down 22% on Latin American pricing pressure.
  3. FY 2025 net sales rose 3% to $17.40B (organic +4%), with GAAP EPS from continuing operations of $1.75 (+43%) and operating EPS of $3.34 (+30%).
  4. Seed delivered FY segment EBITDA of $2.64B (+19%) and margin expansion of about 340 bps; Crop Protection volume grew 5% but price fell 2%.
  5. Free cash flow was $2.9B (+69%) and cash returned to shareholders exceeded $1.5B for the year.
  6. Bayer litigation settlement accelerates royalty neutrality to 2026 (two years early), expands out-licensing in corn, canola and cotton, and is estimated to add about $1B of earnings upside over a decade, against a $610M cash outflow mostly in Q1 2026.
  7. 2026 guidance calls for operating EBITDA of $4.0-$4.2B and operating EPS of $3.45-$3.70, about 7% growth at the midpoint; separation remains on track for 2H 2026.

03—Questions

Frequently Asked Questions

  1. Why did GAAP earnings swing to a loss in Q4 2025 when full-year results were strong?

    The Q4 GAAP loss of $537M was driven mainly by a $610M pre-tax charge (about $470M after tax, or $0.70 per share) for the resolution of litigation with Bayer, plus a $132M tax charge from a valuation allowance on a Brazilian entity's deferred tax assets. These are treated as significant items and excluded from operating EPS, which was $0.22 for the quarter.

  2. What does the Bayer resolution mean for Corteva's future economics?

    Management says the settlement gives multi-year clarity on technology access and licensing, accelerates the path to royalty neutrality to 2026, and supports the company's transition to a net out-licensor of seed technology. It also expands freedom to operate in corn, canola and cotton, and management estimates about $1B of aggregate earnings upside over the next decade, including earlier availability of triple-stack corn traits for out-licensing (as early as 2027). The upfront cost is $610M in cash, largely in Q1 2026, funded from 2025 free cash flow.

  3. Why was Q4 volume weak, and is it a concern?

    Q4 volume fell 5%, mostly from timing rather than lost demand. North American seed and crop protection deliveries shifted into Q1 2026 due to freight optimization and weather delays, and some Latin American seed volume moved into Q3 2025 ahead of the safrinha season. Investors should expect first-quarter 2026 results to benefit from this shift, though the company did not quantify the amount.

  4. What is the outlook for 2026 and the separation?

    Corteva guides 2026 operating EBITDA to $4.0-$4.2B and operating EPS to $3.45-$3.70, both about 7% growth at the midpoint, and includes about $80M of incremental tariff costs. Crop Protection restructuring charges of $80-$90M are expected in 2026. The company remains on track to complete the planned separation in the second half of 2026, with a new CEO and key executive appointments expected in the first half.

04—Continue

← View all 8-K filings